Correspondence 0001193125-22-296207 from Baudax Bio, Inc. (BXRXQ) (CIK 0001780097)
Baudax Bio, Inc. (BXRXQ) (CIK 0001780097)
Date: Dec. 1, 2022 · CIK: 0001780097 · Accession: 0001193125-22-296207
AI Filing Summary & Sentiment
File numbers found in text: 333-268251
Letter
Baudax Bio, Inc.
490 Lapp Road
Malvern, Pennsylvania 19355
December 1, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, D.C. 20549
Attn: Benjamin Richie and Dorrie Yale
Re: Baudax Bio, Inc.
Registration Statement on Form S-1
SEC File No. 333-268251
Request for Acceleration
Mr. Richie:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Baudax Bio, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-268251), as amended (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 1:00 PM, eastern time, on December 1, 2022, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Troutman Pepper Hamilton Sanders LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Troutman Pepper Hamilton Sanders LLP, by calling Jennifer Porter at (215) 981-4339.
Please feel free to direct any questions or comments concerning this request to Jennifer Porter, Esq. of Troutman Pepper Hamilton Sanders LLP at (215) 981-4339.
BAUDAX BIO, INC.
By:
/s/ Gerri Henwood
Name:
Gerri Henwood
Title:
President and Chief Executive Officer
Cc: Rachael M. Bushey, Troutman Pepper Hamilton Sanders LLP
Show Raw Text
CORRESP 1 filename1.htm CORRESP Baudax Bio, Inc. 490 Lapp Road Malvern, Pennsylvania 19355 December 1, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Benjamin Richie and Dorrie Yale Re: Baudax Bio, Inc. Registration Statement on Form S-1 SEC File No. 333-268251 Request for Acceleration Mr. Richie: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Baudax Bio, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-268251), as amended (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 1:00 PM, eastern time, on December 1, 2022, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Troutman Pepper Hamilton Sanders LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Troutman Pepper Hamilton Sanders LLP, by calling Jennifer Porter at (215) 981-4339. Please feel free to direct any questions or comments concerning this request to Jennifer Porter, Esq. of Troutman Pepper Hamilton Sanders LLP at (215) 981-4339. BAUDAX BIO, INC. By: /s/ Gerri Henwood Name: Gerri Henwood Title: President and Chief Executive Officer Cc: Rachael M. Bushey, Troutman Pepper Hamilton Sanders LLP